

Live med lungeroff

Sponsorship Agreement

Between

Pierre Fabre Pharma Norden AB (" Pierre Fabre"), Turebergs Torg 1, 191 47 Sollentuna, Sweden Org.nr: 556517-9305

and

Patientforeningen Lungekræft, v/ formand Lisbeth Søbæk Hansen, Møllehaven 8,4040 Jyllinge, Denmark CVR: 33848072.

1. Background of the agreement

Patientföreningen Lungekræft is publishing a book with patient stories on Lungcancer, a booklet on palliation and and also to create a children's book age 9-12 yrs during 2018 with the financial support from Pierre Fabre Pharma Norden AB. A lot of patients are alone in their diagnosis and have a great helping reading/knowing about other patients in the same situation.

2. Project Description

Pierre Fabre Pharma Norden has agreed to sponsor the costs in producing the book: "Livet med Lungekræft" and the booklet on palliation and a children's book on Lungcancer age 9-12 yrs. The three project is more described in the attachments.

3. Financial Terms

Pierre Fabre has agreed to finance the meeting with about 15.000 DKK excl. tax The organizer will repay any surplus when the final statement of the costs is available.

4. Consultation and Evaluation

Pierre Fabre has appointed Kirsten Sandahl as liaison on matters related to this agreement.

5. Terms and early termination

- 5.1 This agreement is valid from 2018-02-12 -to 2018-12-31.
- 5.2 If any of the parties to make a significant breach of its obligations under this agreement and fails to correct within thirty (30) days of the breach Party in writing invited to, the other party may immediately terminate this Agreement.

6. Ethics and Transparency

The agreement will be performed in accordance with the pharmaceutical industry Ethical rules. Support from pharmaceutical companies for activities / conferences intended for employees in the health services must meet the following conditions:

- (I) The sponsorship is done to support healthcare or research;
- (Ii) the sponsor record of the sponsorship provided, and



(Iii) The sponsorship is not an incentive to recommend, prescribe, purchase, supply, sell or administer specific drugs.

All sponsoring associations / networks of experts shall be transparent and that the information should be reported. The present agreement shall be governed by and construed in accordance with the laws of Denmark. Any dispute that may arise relating to the interpretation or performance of the present agreement that cannot be amicably settled shall fall within the jurisdiction of Denmark.

We would like to draw attention to the new Danish rules, which came into force in November 2014 concerning Health and healthcare professionals review of financial support: under the new rules we must inform you of the rules in § 27 of Decree 1153 of 22 October 2014 and Health Act §§ 202 b and 202 c, including your duty to notify Sundhedsstyrelsen and Sundhedsstyrelsen's publication of this information. http://sundhedsstyrelsen.dk/da/medicin/samarbejde-med-virksomhed/oekonomisk-stoette/sundhedsog-fagpersoner

The parties agree that the content of this agreement may be communicated to a third party will also be entitled to take part in the agreement.

7. Dispute

If a dispute arises in respect of this Agreement, the Parties shall give priority to solving the dispute through negotiations. In the event the parties do not reach agreement within thirty (30) days after the negotiations have been initiated by one party, the dispute shall be resolved by a Danish court.

This Agreement is signed in two (2) identical copies of which each party has received one.

Patientföreningen Lungekræft

Place and Date:

Signature:

Patientforeningen Lungekræft Lisbeth Søbæk Hansen, Formand Pierre Fabre Pharma Norden AB

Place and Date:

Signature:

Marc Vincenti, Director

Pierre Fabre Pharma Norden AB